Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia Corp’s Chief Business Officer, Jason Adair, reported new equity awards. On January 16, 2026, he was granted 27,683 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These RSUs vest with 25% on January 11, 2027 and 6.25% every three months thereafter.
On the same date, he was also granted 41,525 performance stock units (PSUs), which also convert into common stock one-for-one. The PSUs follow a similar time-based vesting schedule tied to the Initial Vesting Date or the filing of the company’s Form 10-K for the year ending December 31, 2026, and include a milestone condition based on 2026 net product sales revenue from YUTREPIA. After these transactions, Adair beneficially owned 211,857 shares of common stock and 41,525 PSUs, all held directly.
Liquidia Corp’s Chief Accounting Officer, Dana Boyle, reported new equity awards on a Form 4. On January 16, 2026, Boyle received 23,728 restricted stock units (RSUs)$0, bringing directly owned common stock (including unvested RSUs and ESPP shares) to 180,428 shares after the transaction. RSUs convert into common shares on a one-for-one basis and follow a vesting schedule where 25% vests on January 11, 2027, with 6.25% vesting every three months thereafter.
Boyle was also granted 35,592 performance stock units (PSUs) on the same date, also at $0 per unit. PSUs convert into common stock on a one-for-one basis and vest over time, starting with 25% on the same initial vesting date (or when the company files its Form 10-K for the year ending December 31, 2026, if later), and 6.25% every three months after that. Vesting of these PSUs depends on a milestone tied to 2026 net product sales revenue from YUTREPIA as disclosed in Liquidia’s FY2026 Form 10-K.
Liquidia Corp Chief Executive Officer and director Roger Jeffs reported new stock-based awards and updated his holdings. On January 16, 2026, he received 115,344 shares of common stock for $0, representing restricted stock units that convert one-for-one into common shares. On the same date, he was granted 173,016 performance stock units, also at $0, each convertible into one share of common stock.
The RSUs vest with 25% on January 11, 2027 and 6.25% every three months afterward. The PSUs follow a similar time-based schedule but vest only if a milestone is met, based on the percentage of units tied to 2026 net product sales revenue from YUTREPIA as disclosed in the company’s FY2026 Form 10-K. After these grants, Jeffs directly owns 1,152,872 common shares, with additional indirect holdings through a living trust and Serendipity BioPharma LLC.
Liquidia Corp insider Michael Kaseta, the CFO and COO, reported new equity awards. On January 16, 2026, he received 59,320 shares of common stock in the form of restricted stock units granted at $0 per share, bringing his directly held common stock to 410,239 shares. These RSUs convert into common stock on a one-for-one basis and vest over time, with 25% vesting on January 11, 2027 and the remainder vesting quarterly thereafter.
Kaseta was also granted 88,980 performance stock units at $0 per unit, each linked to one share of common stock. These PSUs vest on a similar time schedule, but only if a milestone is met based on 2026 net product sales revenue from YUTREPIA as disclosed in Liquidia’s Form 10-K for the year ending December 31, 2026. This structure ties a significant portion of his potential equity compensation to both continued service and specific revenue performance.
Liquidia Corp’s Chief Development Officer, Sanjeev Khindri, reported a stock-based award related to 34,274 shares of common stock on January 16, 2026. These shares reflect restricted stock units (RSUs) that convert into common stock on a one-for-one basis at no cash cost to him.
According to the filing, 71,266 shares of common stock are beneficially owned following this transaction, consisting entirely of unvested RSUs. The vesting schedule states that 25% of the RSUs vest on January 11, 2027, with an additional 6.25% vesting every three months thereafter.
Liquidia Corp Chief Human Resource Officer Sarah Krepp received new equity awards that increase her stake in the company. On January 16, 2026, she was granted 23,728 restricted stock units (RSUs) that convert into common stock on a one-for-one basis at no cash cost. After this grant, she beneficially owns 164,497 shares of common stock, including previously granted unvested RSUs and shares acquired under the employee stock purchase plan.
On the same date, she was also granted 35,592 performance stock units (PSUs), which also convert into common stock one-for-one and were reported at a price of $0. Both the RSUs and PSUs follow a similar time-based schedule in which 25% vest on January 11, 2027 (or, for PSUs, potentially when the company files its Form 10-K for 2026) and 6.25% vest every three months thereafter, with the PSUs additionally requiring a milestone based on 2026 net product sales revenue from YUTREPIA.
Liquidia Corp’s Chief Commercial Officer, Scott Moomaw, reported new equity awards. On January 16, 2026, he received 32,955 shares of common stock in the form of restricted stock units (RSUs) at $0 per share, which convert into common stock on a one-for-one basis and vest 25% on January 11, 2027, with 6.25% vesting every three months thereafter. After this grant, he directly beneficially owned 187,469 shares of common stock, including multiple prior RSU grants and shares from the employee stock purchase plan. He was also granted 49,433 performance stock units (PSUs), which convert one-for-one into common stock and vest over time starting on the initial vesting date or the filing of the company’s Form 10-K for 2026, subject to a milestone based on 2026 net product sales revenue from YUTREPIA.
Liquidia Corp's Chief Medical Officer, Dr. Rajeev Saggar, reported new equity awards. He received 32,955 restricted stock units (RSUs)January 11, 2027, with 6.25% vesting every three months thereafter.
Following this grant and prior awards, Dr. Saggar beneficially owns 209,838 shares of common stock, including unvested RSUs and shares acquired under the 2020 Employee Stock Purchase Plan. He was also granted 49,433 performance stock units (PSUs) that convert into common stock one-for-one. These PSUs vest 25% on the Initial Vesting Date or when the company files its Form 10-K for the year ending December 31, 2026, with additional 6.25% vesting quarterly, subject to a milestone based on 2026 net product sales revenue from YUTREPIA as disclosed in that Form 10-K.
Liquidia Corp’s general counsel, Russell Schundler, reported new equity awards and updated holdings. On January 16, 2026, he was granted 32,955 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These RSUs vest with 25% vesting on January 11, 2027, then 6.25% every three months after that.
He was also granted 49,433 performance stock units (PSUs), each convertible into one share of common stock. The PSUs vest 25% on the same initial vesting date (or, if later, when the company files its Form 10-K for 2026) and 6.25% every three months thereafter, subject to a milestone based on 2026 net product sales revenue from YUTREPIA as disclosed in the FY2026 Form 10-K. Following these grants, he beneficially owns 612,349 shares of common stock directly and 49,433 PSUs, plus 14,500 shares held indirectly by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, reported equity compensation activity and a related share sale. On January 9, 2026, 12,716 performance stock units converted into the same number of common shares at an exercise price of $0, increasing her directly held common stock to 153,934 shares and leaving 38,145 derivative securities beneficially owned. On January 12, 2026, she sold 13,165 common shares at $37.43 per share, primarily to cover taxes tied to the settlement of RSUs and PSUs granted in 2024 and 2025 under company plans. After these transactions, she directly held 140,769 common shares, alongside sizable unvested RSU and PSU awards that continue to vest over time.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
